Ingenia Therapeutics Goes Public on KOSDAQ

MT Newswires Live

08/18

Ingenia Therapeutics, a clinical-stage biotechnology company, has gone public on South Korea's KOSDAQ market, according to a statement on Tuesday.

Founded in Boston in 2018, the company uses two proprietary technologies designed to repair weakened blood vessels and clear out harmful proteins that drive disease.

Its lead drug candidate, IGT-427, is being tested in late-stage trials for two serious eye conditions-age-related macular degeneration and diabetic macular edema.

The program continues through a licensing deal with Merck, which acquired Ingenia's partner EyeBio in 2024.

The IPO funds will also speed up development of other treatments, including IGT-303 for chronic kidney disease (currently in mid-stage patient trials) and IGT-532 for solid tumors

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2660465414"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2660465414\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2660465414?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-18 17:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660465414","market":"sh","top_or_hot":-1,"title":"Ingenia Therapeutics Goes Public on KOSDAQ","media":"MT Newswires Live","content":"<html><body><p> Ingenia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, a clinical-stage biotechnology company, has gone public on South Korea's KOSDAQ market, according to a statement on Tuesday.</p><p>Founded in Boston in 2018, the company uses two proprietary technologies designed to repair weakened blood vessels and clear out harmful proteins that drive disease.</p><p>Its lead drug candidate, IGT-427, is being tested in late-stage trials for two serious eye conditions-age-related macular degeneration and diabetic macular edema.</p><p>The program continues through a licensing deal with Merck, which acquired Ingenia's partner EyeBio in 2024.</p><p>The IPO funds will also speed up development of other treatments, including IGT-303 for chronic kidney disease (currently in mid-stage patient trials) and IGT-532 for solid tumors</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ingenia Therapeutics Goes Public on KOSDAQ</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIngenia Therapeutics Goes Public on KOSDAQ\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-08-18 17:33</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Ingenia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, a clinical-stage biotechnology company, has gone public on South Korea's KOSDAQ market, according to a statement on Tuesday.</p><p>Founded in Boston in 2018, the company uses two proprietary technologies designed to repair weakened blood vessels and clear out harmful proteins that drive disease.</p><p>Its lead drug candidate, IGT-427, is being tested in late-stage trials for two serious eye conditions-age-related macular degeneration and diabetic macular edema.</p><p>The program continues through a licensing deal with Merck, which acquired Ingenia's partner EyeBio in 2024.</p><p>The IPO funds will also speed up development of other treatments, including IGT-303 for chronic kidney disease (currently in mid-stage patient trials) and IGT-532 for solid tumors</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"半新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2660465414","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2660465414","pubTimestamp":1787045589,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ingenia Therapeutics, a clinical-stage biotechnology company, has gone public on South Korea's KOSDAQ market, according to a statement on Tuesday.Founded in Boston in 2018, the company uses two proprietary technologies designed to repair weakened blood vessels and clear out harmful proteins that drive disease.Its lead drug candidate, IGT-427, is being tested in late-stage trials for two serious eye conditions-age-related macular degeneration and diabetic macular edema.The program continues through a licensing deal with Merck, which acquired Ingenia's partner EyeBio in 2024.The IPO funds will also speed up development of other treatments, including IGT-303 for chronic kidney disease  and IGT-532 for solid tumors","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","LENZ":"Therapeutics","BK4139":"生物科技","BK4007":"制药"},"translate_title":"Ingenia Therapeutics 在 KOSDAQ 上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5},"content_text":"Ingenia Therapeutics, a clinical-stage biotechnology company, has gone public on South Korea's KOSDAQ market, according to a statement on Tuesday.Founded in Boston in 2018, the company uses two proprietary technologies designed to repair weakened blood vessels and clear out harmful proteins that drive disease.Its lead drug candidate, IGT-427, is being tested in late-stage trials for two serious eye conditions-age-related macular degeneration and diabetic macular edema.The program continues through a licensing deal with Merck, which acquired Ingenia's partner EyeBio in 2024.The IPO funds will also speed up development of other treatments, including IGT-303 for chronic kidney disease (currently in mid-stage patient trials) and IGT-532 for solid tumors","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}